Of additional importance, adjacent normal lung tissue appeared to be unaffected by FAK TKI treatments alone or in combination with erlotinib (Fig 2C), suggesting a potential selective inhibition of NSCLC tumors. This evidence concerns the gene PTK2 and non-small cell lung carcinoma.